The symptom that outlasts the mood

Depression's most discussed symptoms — low mood, loss of interest, disrupted sleep — tend to get the most clinical attention and the most treatment options. What often goes comparatively unaddressed is what happens to memory and concentration even after someone's mood has genuinely improved. Dr. Angharad de Cates, a National Institute for Health and Care Research clinical lecturer at the University of Birmingham and honorary member of the University of Oxford's Department of Psychiatry, described the gap directly: "Cognitive problems, or brain fog, are an important and often overlooked feature of depression, and can persist even when mood improves."

A new proof-of-concept study, published in the journal Psychological Medicine and led by de Cates alongside senior author Professor Susannah Murphy of Oxford, tested whether an existing, widely available drug might help close that gap. The drug in question, prucalopride, has nothing to do with mood or cognition on its approved label — it's licensed specifically to treat chronic constipation. What led researchers to test it here was a specific piece of underlying neuroscience: prucalopride works by stimulating the serotonin 5-HT4 receptor, a receptor found in both the gut and the brain, and earlier research had already suggested that targeting this particular receptor could improve memory, including in healthy volunteers who had never experienced depression.

Why researchers needed to test it specifically in people with depression

That earlier work left an important, unanswered question: did prucalopride's cognitive benefit in healthy volunteers actually translate to people who had experienced depression, given that depression itself is known to alter brain chemistry and cognitive function in ways that don't necessarily mirror a healthy brain's baseline responses to a given drug. A treatment's effect in one population doesn't automatically generalize to another, and this study was specifically designed to close that gap by testing the drug directly in the population it was intended to help.

Researchers recruited 50 adults with a documented history of depression, all of whom had recovered from their most recent depressive episode at least six months prior to enrolling in the study — a design choice meant to isolate lingering cognitive symptoms from the drug's more commonly documented effects during an active depressive episode. Participants were randomly assigned in a double-blind, placebo-controlled design to receive either 2 milligrams of prucalopride, the standard dose already licensed for chronic constipation, or an inactive placebo, for a period of seven to ten days.

What the cognitive testing actually measured

Before and after the treatment period, every participant completed a battery of cognitive assessments designed to measure several distinct dimensions of mental function: executive function, short-term memory, long-term memory, and separately, emotional cognition — sometimes referred to as "hot" cognition, in contrast to the more neutral, non-emotional "cold" cognitive tasks that made up the bulk of the testing. That distinction between cold and hot cognition matters methodologically, since depression is known to affect emotional processing and neutral information processing somewhat differently, and testing both separately allows researchers to identify more precisely which cognitive domains a treatment actually influences.

The results showed a clear pattern specifically within the cold, non-emotional cognitive domain. Participants who received prucalopride demonstrated significantly better performance than the placebo group across multiple objective measures, showing both higher accuracy scores and faster response times on tasks measuring memory and executive functioning. De Cates summarized the finding plainly: participants who took prucalopride "performed significantly better" than those given placebo, gains that showed up consistently across several different cognitive measures rather than in just one isolated test.

A drug that didn't come with the typical trade-offs

One of the more clinically relevant findings from this trial is what didn't happen: the study reported no significant side effects among participants taking prucalopride. De Cates specifically addressed the most obvious potential concern given the drug's approved use as a laxative, noting that participants didn't experience notable gastrointestinal complaints beyond the medication's known, gentle bowel-stimulating effect. That's a meaningful detail for a drug being considered for a new therapeutic purpose — a treatment that shows cognitive benefit but comes bundled with disruptive digestive side effects would face a much harder path toward broader clinical adoption than one that appears comparatively well tolerated at its already-established dose.

Professor Murphy, the study's senior author, framed why closing this specific treatment gap matters so much for patients: "For many people, recovery from depression is incomplete because difficulties with memory and concentration persist." That's a distinction worth sitting with — a person can meet every clinical criterion for depression remission, no longer meeting diagnostic thresholds for low mood, while still experiencing meaningful day-to-day impairment in their ability to concentrate, remember information, or think as quickly as they did before their depressive episode began.

Why outside experts are urging caution before drawing firm conclusions

Independent commentary on the study has been notably measured about what these findings do and don't establish. Dr. Nina Kraguljac, executive vice chair of the Department of Psychiatry at a separate academic institution, who wasn't involved in the research, praised the work while raising specific methodological questions. She noted uncertainty about whether differences in intelligence, or IQ, between the treatment and placebo groups might have influenced the results, and pointed out that the study didn't establish whether participants had clinically significant cognitive impairment at baseline before treatment began — meaning it remains unclear whether prucalopride is improving genuinely impaired cognition or simply producing a modest performance boost in people whose cognitive function may not have been meaningfully compromised to begin with.

Kraguljac's broader framing is worth taking seriously: "An improvement on a task of performance is nice to demonstrate, but it's only the first step toward testing if these drugs are actually effective for cognition." That's an important distinction between demonstrating a measurable statistical effect in a controlled trial setting and demonstrating genuine, clinically meaningful improvement in how someone actually functions in daily life — memory tasks performed in a research lab don't automatically translate into a patient feeling less mentally foggy at work or in conversation with family.

What comes next before this reaches everyday clinical use

It's important to be clear about the scope of what this study actually shows: this was a proof-of-concept trial involving just 50 participants over a short seven-to-ten-day treatment window, not a large-scale clinical trial establishing prucalopride as an approved or recommended treatment for depression-related cognitive symptoms. De Cates herself cautioned that considerably more research is still needed before clinicians could reasonably recommend the drug specifically to address cognitive symptoms in people with a history of depression, regardless of how encouraging these initial results look.

That said, the underlying logic connecting the serotonin 5-HT4 receptor to memory and executive function, now demonstrated consistently in both healthy volunteers and, in this newer trial, specifically in people with a history of depression, gives researchers a genuinely promising and replicable target to continue investigating. Given that prucalopride is already an approved, widely available medication with an established safety profile for its original use, any future larger trials confirming these cognitive benefits would face a considerably shorter path toward potential clinical application than an entirely new, unapproved compound would require — though, as both de Cates and outside reviewers like Kraguljac emphasize, that confirmation is still a meaningful distance away.

*This article was researched using publicly available reporting from Psychological Medicine, ScienceDaily, Medscape Medical News, Technology Networks, Medical Xpress, SciTechDaily, and SSBCrack News coverage of the peer-reviewed study led by Dr. Angharad de Cates and Professor Susannah Murphy. It is intended for informational purposes and is not medical advice. If you are experiencing persistent depression symptoms or cognitive difficulties, please consult a doctor or mental health professional.*